Person:
ERSOY, YELIZ EMINE

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
YELIZ EMINE
Last Name
ERSOY
Name
Email Address
Birth Date

Filters

20151
Reset filters

Settings

Subject: Breast carcinoma ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    Estrogen Receptor Positive/Progesterone Receptor Negative Breast Carcinomas: A Subgroup Deserves Particular Interest
    (2015-08-01) Gucin, ZÜHAL; GECER, Melin Ozgun; Buyukpinarbasili, NUR; SONMEZ, Cavide; Ersoy, YELİZ EMİNE; MUSLUMANOGLU, Mahmut; GÜCİN, ZÜHAL; BÜYÜKPINARBAŞILI, NUR; ERSOY, YELIZ EMINE
    Objective: Breast carcinomas positive for the estrogen receptor (ER+) but negative for the progesterone receptor (PR−) have unfavorable prognostic features and are resistant to tamoxifen therapy. The goal of this study was to highlight the significance of PR− breast carcinomas. Methods: Therefore, 146 breast carcinomas comprising 87 ER+/PR+ and 59 ER+/PR− carcinomas were examined. These two groups were compared in terms of age; tumor type; tumor size; histologic grade; presence of an in situ component; lymphovascular and perineural invasion; and ER, PR, c-Erb B2, Ki-67, and epidermal growth factor receptor (EGFR) status. Results: While the number of metastatic lymph node and related pN2+pN3 tumors were found to be significantly higher in the ER+/ PR− group, the differences with respect to the tumor size, metastatic lymph node size, and frequency of lymphovascular invasion were nearly significant. Conclusion: ER+/PR− tumors have an unfavorable prognosis and show a clinical behavior closer to triple negative ones, although classified as luminal tumors. Revealing the mechanisms causing these differences will enhance the success of breast cancer therapy.